We read with interest the article by Morrison et al. on acute hypertriglyceridemia secondary to tocilizumab in patients with severe COVID-19. (1) One patient also had pancreatitis, a dreaded complication of hypertriglyceridemia. Both patients were already on lopinavir/ritonavir before tocilizumab (added day 9 and day 13) was added. Propofol was briefly used. This article is protected by copyright. All rights reserved.